Hangzhou Biotest Biotech Co.,Ltd.

Equities

688767

CNE1000050H0

Medical Equipment, Supplies & Distribution

End-of-day quote Shanghai S.E. 06:00:00 2024-05-30 pm EDT 5-day change 1st Jan Change
28.51 CNY +0.92% Intraday chart for Hangzhou Biotest Biotech Co.,Ltd. -0.07% -5.81%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Hangzhou Biotest Biotech Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Hangzhou Biotest Biotech Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Tranche Update on Hangzhou Biotest Biotech Co.,Ltd.'s Equity Buyback Plan announced on November 6, 2023. CI
Hangzhou Biotest Biotech Co.,Ltd.(XSSC:688767) dropped from S&P Global BMI Index CI
Biotest Biotech to Repurchase Up to 100 Million Yuan Shares MT
Hangzhou Biotest Biotech Co.,Ltd. announces an Equity Buyback for CNY 100 million worth of its shares. CI
Hangzhou Biotest Biotech Co.,Ltd. authorizes a Buyback Plan. CI
Hangzhou Biotest Biotech Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Hangzhou Biotest Biotech Co.,Ltd.(XSSC:688767) added to S&P Global BMI Index CI
Hangzhou Biotest Biotech Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Hangzhou Biotest Biotech Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Hangzhou Biotest Biotech Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Hangzhou Biotest’s COVID-19 Antigen Home Test Kit Cleared by US FDA for Emergency Use MT
Hangzhou Biotest Biotech Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Hangzhou Biotest Biotech Co.,Ltd.(SHSE:688767) added to Shanghai Stock Exchange Composite Index CI
Hangzhou Biotest Biotech Co.,Ltd.(SHSE:688767) added to Shanghai Stock Exchange A Share Index CI
Certain A Shares of Hangzhou Biotest Biotech Co.,Ltd. are subject to a Lock-Up Agreement Ending on 8-SEP-2022. CI
Hangzhou Biotest Biotech Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Hangzhou Biotest Biotech Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Hangzhou Biotest Biotech Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Australia regulator to review price hike in COVID-19 antigen tests RE
Chart Hangzhou Biotest Biotech Co.,Ltd.
More charts
Hangzhou Biotest Biotech Co Ltd is a company mainly engaged in the research and development (R&D), production and sales of point-of-care testing (POCT) diagnostic reagents. The Company's products include reproductive health testing series, such as human chorionic gonadotropin testing reagent and luteinizing hormone testing reagent, and drug abuse testing series, such as morphine testing reagent and cocaine testing reagent, and infectious disease testing series, such as adenovirus testing reagent and typhoid antibody testing reagent, and tumor marker testing series, such as alpha fetoprotein detection reagent, and myocardial marker detection series, such as dimer detection reagent and myocardial series detection reagent.
More about the company
  1. Stock Market
  2. Equities
  3. 688767 Stock
  4. News Hangzhou Biotest Biotech Co.,Ltd.
  5. Hangzhou Biotest’s COVID-19 Antigen Home Test Kit Cleared by US FDA for Emergency Use